Recent Updates
Recently added Catalysts
ILMN Positive Sentiment Score: 75/100

Element Biosciences Prevails in German Patent Case Against Illumina

Tuesday, July 14, 2026 1 min read
Key Takeaway: Element Biosciences has secured a favorable ruling from the Regional Court of Munich I, determining that Illumina infringed on its patent rights related to an imaging method for DNA sequencing. The court found both direct and indirect infringement by Illumina, which may impact their operations in Germany. This ruling strengthens Element's position in the competitive biopharma landscape.
Price reaction · baseline $190.05 (2026-07-13 close) · hit pre-market · 1 other ILMN headline(s) in the window, move may be shared
day 0 close · peak
+0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Element Biosciences wins a significant legal victory.
  • The court ruling reinforces Element's patent rights.
  • The decision could enhance Element's market position.

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Element Biosciences, Inc. today announced that the Regional Court of Munich I (Landgericht München I) has ruled that Illumina, Inc. and its German subsidiary, Illumina GmbH, infringe patent rights controlled by Element covering an imaging method used in DNA sequencing. The court found Illumina liable for both direct infringement, through Illumina's own use of the patented method in Germany, and indirect infringement, through the offer and supply of sequencing systems

Frequently Asked Questions

What was the court's ruling in the patent case?

The court ruled that Illumina infringed on Element Biosciences' patent rights.

What method is covered by the patent?

The patent covers an imaging method used in DNA sequencing.

Who was found liable for infringement?

Illumina and its German subsidiary were found liable for both direct and indirect infringement.

Where did the court ruling take place?

The ruling was made by the Regional Court of Munich I in Germany.

Tags: ILMN Viatris Investor Conferences Healthcare Element Biosciences Illumina patent rights DNA sequencing Germany
Last updated: Jul 14, 2026

Biotech snapshot

Cash runway
$1089M liquidity · $0M/mo burn
Low dilution risk
Lead asset
18F-MFBGPhase 3
Neuroblastoma →